• Earlier this month, Vicor’s annual meeting confirmed an eleven-member board and endorsed executive pay, while analysts highlighted strong momentum scores and upward earnings estimate revisions supported by a recent shareholder and analyst call.
• At the same time, a series of scheduled insider stock option exercises and sales, alongside fresh option grants to senior executives, contrasts with generally positive analyst sentiment and suggests investors are weighing governance, incentives, and growth expectations together.
• We’ll now examine how this combination of upbeat earnings revisions and ongoing insider selling activity may shape Vicor’s investment narrative.

AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Vicor Investment Narrative Recap

To own Vicor, you have to believe its AI and high performance power products, plus IP licensing, can justify a very rich valuation and volatile earnings. The most important near term catalyst remains execution on higher product and licensing revenues, while the biggest risk is that demand or licensing flows undershoot expectations. The latest mix of positive earnings estimate revisions and heavy, pre planned insider selling does not appear to change those core drivers in a material way.

Against this backdrop, the cluster of insider option exercises and sales, including CEO and CFO transactions under Rule 10b5-1 plans, stands out as most relevant. It sits alongside a Momentum Style Score of B, a Strong Buy consensus, and an earnings guidance raise to Q2 2026 revenue of about US$142,000,000, sharpening the contrast between upbeat expectations and concerns about how much good news is already priced in.

Yet behind the strong AI and licensing story, investors should still be aware of how low fab utilization and heavy fixed costs could...

Vicor's narrative projects $1.3 billion revenue and $416.1 million earnings by 2029. This requires 45.7% yearly revenue growth and about a $279 million earnings increase from $136.7 million today.

Uncover how Vicor's forecasts yield a $406.25 fair value, a 23% upside to its current price.

Exploring Other Perspectives

Some of the lowest analysts were only modeling about US$552,100,000 of 2029 revenue and US$111,000,000 of earnings, a far slower ramp that could look even more cautious or potentially outdated after this momentum focused news, so it is worth seeing how differently you might weigh Vicor's dependency on a single AI lead customer and its fab utilization risk.

Explore 3 other fair value estimates on Vicor - why the stock might be worth 48% less than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Vicor research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Vicor research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Vicor's overall financial health at a glance.

Searching For A Fresh Perspective?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Find 43 companies with promising cash flow potential yet trading below their fair value.
• This technology could replace computers: discover 29 stocks that are working to make quantum computing a reality.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.